Address
1100 Melville St.
Suite 888
Vancouver, BC
V6E 4A6, Canada
Contact
Nicolas Loebel+14254891123
nloebel@ondinebio.com
Website
Steriwave™ nasal photodisinfection
In minutes, Steriwave destroys nasal pathogens including drug-resistant bacteria, viruses, and fungi
Helps reduce HAIs by 40-80% without harming human tissue or generating AMR. Immediate broad-spectrum efficacy even against superbugs.
Technology:
Microorganisms:
Application:
Development stage:
- Infection prevention
- Antimicrobial stewardship
- Microbial diagnostics
- Antimicrobial compound/strategy
- Removal antibiotics/bacteria
Microorganisms:
- Bacteria
- Viruses
- Fungi
- Yeasts
- Parasites
Application:
- Human
- Veterinary
- AgriFood
- Environmental
- Other
Development stage:
- Development
- Marketed product
- Research
- Validation
- Market entry
Organization:
Partnering:
Funding organisation:
Infectious disease area:
Geographic origin:
- Company
- Academia
- Institute
- NGO
- Government
Partnering:
- License
- Co-develop
- Joint Venture
- Sell
- Outsource
Funding organisation:
- OTHER / NA
- CARB-X
- FIND
- GARDP
- REPAIR
Infectious disease area:
- UTI
- STI
- BSI
- GII
- SSTI
- IAI
- SSI
- RTI
- CNSI
Geographic origin:
- North America
- South America
- Eurasia
- Africa
- Oceania
N.A.
Ondine’s photodisinfection-based therapies help prevent and treat serious infections, including those caused by antimicrobial-resistant pathogens
In addition to Steriwave, Ondine’s pipeline of photodisinfection-based products include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, wounds, and other indications related to HAIs.
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!